{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T17:41:40Z","timestamp":1792086100557,"version":"4.4.0"},"reference-count":116,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Psychiatry"],"published-print":{"date-parts":[[2020,6,1]]},"abstract":"\n Importance<\/jats:title>\n Antidepressants are commonly used worldwide to treat major depressive disorder. Symptomatic response to antidepressants can vary depending on differences between individuals; however, this variability may reflect nonspecific or random factors.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n To investigate the assumption of systematic variability in symptomatic response to antidepressants and to assess whether this variability is associated with severity of major depressive disorder, antidepressant class, or year of study publication.<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n Data used were from a recent network meta-analysis of acute treatment with licensed antidepressants in adults with major depressive disorder. The following databases were searched from inception to January 8, 2016: the Cochrane Central Register of Controlled Trials, CINAHL, Embase, LILACS database, MEDLINE, MEDLINE In-Process, and PsycINFO. Additional sources were international trial registries, drug approval agency websites, and key scientific journals.<\/jats:p>\n <\/jats:sec>\n \n Study Selection<\/jats:title>\n Analysis was restricted to double-blind, randomized placebo-controlled trials with available data at the study\u2019s end point.<\/jats:p>\n <\/jats:sec>\n \n Data Extraction and Synthesis<\/jats:title>\n Baseline and end point means, SDs, number of participants in each group, antidepressant class, and publication year were extracted. The data were analyzed between August 14 and November 18, 2019.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n With the use of validated methods, coefficients of variation were derived for antidepressants and placebo, and their ratios were calculated to compare outcome variability between antidepressant and placebo. Ratios were entered into a random-effects model, with the expectation that response to antidepressants would be more variable than response to placebo. Analysis was repeated after stratifying by baseline severity of depression, antidepressant class (selective serotonin reuptake inhibitors: citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and vilazodone; serotonin and norepinephrine reuptake inhibitors: desvenlafaxine and venlafaxine; norepinephrine-dopamine reuptake inhibitor: bupropion; noradrenergic agents: amitriptyline and reboxetine; and other antidepressants: agomelatine, mirtazapine, and trazodone), and publication year.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n In the 87 eligible randomized placebo-controlled trials (17\u202f540 unique participants), there was significantly more variability in response to antidepressants than to placebo (coefficients of variation ratio, 1.14; 95% CI, 1.11-1.17;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Baseline severity of depression did not moderate variability in response to antidepressants. Variability in response to selective serotonin reuptake inhibitors was lower than variability in response to noradrenergic agents (coefficients of variation ratio, 0.88; 95% CI, 0.80-0.97;\n P<\/jats:italic>\n \u2009=\u2009.01), as was the variability in response to other antidepressants compared with noradrenergic agents (coefficients of variation ratio, 0.87; 95% CI, 0.79-0.97;\n P<\/jats:italic>\n \u2009=\u2009.001). Variability also tended to be lower in studies that were published more recently, with coefficients of variation changing by a value of 0.005 (95% CI, 0.002-0.008;\n P<\/jats:italic>\n \u2009=\u2009.003) for every year a study is more recent.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Individual differences may be systematically associated with responses to antidepressants in major depressive disorder beyond placebo effects or statistical factors. This study provides empirical support for identifying moderators and personalizing antidepressant treatment.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapsychiatry.2019.4815","type":"journal-article","created":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T15:16:10Z","timestamp":1582125370000},"page":"607","source":"Crossref","is-referenced-by-count":36,"title":["RETRACTED: Individual Differences in Response to Antidepressants"],"prefix":"10.1001","volume":"77","author":[{"given":"Marta M.","family":"Maslej","sequence":"first","affiliation":[{"name":"Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki A.","family":"Furukawa","sequence":"additional","affiliation":[{"name":"Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine, School of Public Health, Yoshida-Konoe, Sakyo, Kyoto, Japan"},{"name":"Department of Clinical Epidemiology, Kyoto University Graduate School of Medicine, Kyoto University School of Public Health, Yoshida-Konoe, Sakyo, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Cipriani","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Oxford, Oxford, United Kingdom"},{"name":"Warneford Hospital, Oxford Health National Health Service Foundation Trust, Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.","family":"Andrews","sequence":"additional","affiliation":[{"name":"Department of Psychology, Neuroscience & Behaviour, McMaster University, Hamilton, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit H.","family":"Mulsant","sequence":"additional","affiliation":[{"name":"Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"617","key":"yoi190103r3","doi-asserted-by":"publisher","first-page":"e852","DOI":"10.3399\/bjgp13X675430","article-title":"Prevalence of treatment-resistant depression in primary care: cross-sectional data.","volume":"63","author":"Thomas","year":"2013","journal-title":"Br J Gen Pract"},{"key":"yoi190103r4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jad.2019.03.031","article-title":"Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials.","volume":"250","author":"Noma","year":"2019","journal-title":"J Affect Disord"},{"issue":"3","key":"yoi190103r5","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3109\/10673229.2011.586551","article-title":"Genes, environment, and individual differences in responding to treatment for depression.","volume":"19","author":"Uher","year":"2011","journal-title":"Harv Rev Psychiatry"},{"key":"yoi190103r6","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.1530","article-title":"Evaluation of differences in individual treatment response in schizophrenia spectrum disorders: a meta-analysis","author":"Winkelbeiner","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"yoi190103r7","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/sim.6739","article-title":"Mastering variation: variance components and personalised medicine.","volume":"35","author":"Senn","year":"2016","journal-title":"Stat Med"},{"issue":"1","key":"yoi190103r8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1017\/S204579601600007X","article-title":"Are personalised treatments of adult depression finally within reach?","volume":"26","author":"Cuijpers","year":"2017","journal-title":"Epidemiol Psychiatr Sci"},{"issue":"1","key":"yoi190103r9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/YCO.0000000000000377","article-title":"The potential of predictive analytics to provide clinical decision support in depression treatment planning.","volume":"31","author":"Kessler","year":"2018","journal-title":"Curr Opin Psychiatry"},{"key":"yoi190103r10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/1741-7015-11-132","article-title":"Personalized medicine in psychiatry: problems and promises.","volume":"11","author":"Ozomaro","year":"2013","journal-title":"BMC Med"},{"issue":"12","key":"yoi190103r11","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1176\/appi.ajp.2010.09111680","article-title":"Personalized medicine for depression: can we match patients with treatments?","volume":"167","author":"Simon","year":"2010","journal-title":"Am J Psychiatry"},{"issue":"8","key":"yoi190103r12","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1001\/archpsyc.65.8.870","article-title":"Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features.","volume":"65","author":"Rush","year":"2008","journal-title":"Arch Gen Psychiatry"},{"key":"yoi190103r13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jpsychires.2016.03.001","article-title":"Establishing moderators and biosignatures of antidepressant response in clinical care (EMBARC): rationale and design.","volume":"78","author":"Trivedi","year":"2016","journal-title":"J Psychiatr Res"},{"issue":"8","key":"yoi190103r14","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1176\/ajp.148.8.997","article-title":"Patient predictors of response to psychotherapy and pharmacotherapy: findings in the NIMH Treatment of Depression Collaborative Research Program.","volume":"148","author":"Sotsky","year":"1991","journal-title":"Am J Psychiatry"},{"issue":"4","key":"yoi190103r15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/jamapsychiatry.2017.0025","article-title":"Reevaluating the efficacy and predictability of antidepressant treatments: a symptom clustering approach.","volume":"74","author":"Chekroud","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"yoi190103r16","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jad.2014.10.010","article-title":"Depression is not a consistent syndrome: an investigation of unique symptom patterns in the STAR*D study.","volume":"172","author":"Fried","year":"2015","journal-title":"J Affect Disord"},{"issue":"1","key":"yoi190103r17","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/jclp.20213","article-title":"Meta-analysis of the factor structures of four depression questionnaires: Beck, CES-D, Hamilton, and Zung.","volume":"62","author":"Shafer","year":"2006","journal-title":"J Clin Psychol"},{"issue":"1","key":"yoi190103r18","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/jama.2009.1943","article-title":"Antidepressant drug effects and depression severity: a patient-level meta-analysis.","volume":"303","author":"Fournier","year":"2010","journal-title":"JAMA"},{"issue":"10128","key":"yoi190103r20","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"yoi190103r21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-010919","article-title":"Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis.","volume":"6","author":"Furukawa","year":"2016","journal-title":"BMJ Open"},{"issue":"1","key":"yoi190103r22","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression.","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"yoi190103r26","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change.","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"issue":"1","key":"yoi190103r27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0165-1781(86)90060-0","article-title":"The Inventory for Depressive Symptomatology (IDS): preliminary findings.","volume":"18","author":"Rush","year":"1986","journal-title":"Psychiatry Res"},{"issue":"5220","key":"yoi190103r28","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1126\/science.7604277","article-title":"Sex differences in mental test scores, variability, and numbers of high-scoring individuals.","volume":"269","author":"Hedges","year":"1995","journal-title":"Science"},{"issue":"2","key":"yoi190103r29","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/2041-210X.12309","article-title":"Meta-analysis of variation: ecological and evolutionary applications and beyond.","volume":"6","author":"Nakagawa","year":"2015","journal-title":"Methods Ecol Evol"},{"issue":"3","key":"yoi190103r30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package.","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"issue":"1","key":"yoi190103r33","doi-asserted-by":"publisher","first-page":"66","DOI":"10.4088\/JCP.11m06831","article-title":"Short-term dynamic psychotherapy versus pharmacotherapy for major depressive disorder: a randomized, placebo-controlled trial.","volume":"73","author":"Barber","year":"2012","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"yoi190103r35","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/01.JGP.0000194645.70869.3b","article-title":"A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.","volume":"14","author":"Schatzberg","year":"2006","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"yoi190103r38","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/mp.2015.53","article-title":"Consistent superiority of selective serotonin reuptake inhibitors over placebo in reducing depressed mood in patients with major depression.","volume":"21","author":"Hieronymus","year":"2016","journal-title":"Mol Psychiatry"},{"issue":"2","key":"yoi190103r39","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/JCP.0b013e3181d420a7","article-title":"Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial.","volume":"30","author":"Zajecka","year":"2010","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"yoi190103r42","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/YIC.0b013e32831980f2","article-title":"Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features.","volume":"24","author":"Sheehan","year":"2009","journal-title":"Int Clin Psychopharmacol"},{"issue":"3-4","key":"yoi190103r43","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0165-0327(84)90051-X","article-title":"A double-blind comparison of fluvoxamine, imipramine and placebo in depressed patients.","volume":"7","author":"Norton","year":"1984","journal-title":"J Affect Disord"},{"issue":"1","key":"yoi190103r44","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1590\/S1516-44462006000100007","article-title":"Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression: a randomized double-blind trial in a Brazilian sample.","volume":"28","author":"Moreno","year":"2006","journal-title":"Braz J Psychiatry"},{"key":"yoi190103r45","first-page":"247","article-title":"A double-blind comparative study of oxaprotiline with amitriptyline and placebo in moderate depression.","volume":"32","author":"Roffman","year":"1982","journal-title":"Curr Ther Res"},{"issue":"4","key":"yoi190103r46","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3109\/10401239809147030","article-title":"A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression.","volume":"10","author":"Fava","year":"1998","journal-title":"Ann Clin Psychiatry"},{"key":"yoi190103r47","first-page":"871","article-title":"A dose-response study of escitalopram in patients with major depressive disorder: a placebo-controlled, double-blind study.","volume":"14","author":"Hirayasu","year":"2011","journal-title":"Jpn J Clin Psychopharmacol"},{"issue":"4","key":"yoi190103r48","first-page":"559","article-title":"Fluoxetine in major depression: a controlled study.","volume":"39","author":"Rickels","year":"1986","journal-title":"Curr Ther Res Clin Exp"},{"issue":"3-4","key":"yoi190103r51","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jpsychires.2005.07.009","article-title":"A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients.","volume":"41","author":"Nemeroff","year":"2007","journal-title":"J Psychiatr Res"},{"issue":"2-3","key":"yoi190103r52","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S0165-0327(99)00067-1","article-title":"A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression.","volume":"56","author":"Rudolph","year":"1999","journal-title":"J Affect Disord"},{"issue":"5","key":"yoi190103r53","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/01.jcp.0000178416.60426.29","article-title":"A double-blind, randomized trial of St John\u2019s wort, fluoxetine, and placebo in major depressive disorder.","volume":"25","author":"Fava","year":"2005","journal-title":"J Clin Psychopharmacol"},{"issue":"7","key":"yoi190103r54","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1176\/appi.ajp.160.7.1277","article-title":"An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression.","volume":"160","author":"Schneider","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"5","key":"yoi190103r55","first-page":"20","article-title":"Extended-release trazodone in major depressive disorder: a randomized, double-blind, placebo-controlled study.","volume":"6","author":"Sheehan","year":"2009","journal-title":"Psychiatry (Edgmont)"},{"issue":"5","key":"yoi190103r56","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/00004850-200209000-00004","article-title":"Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study.","volume":"17","author":"L\u00f4o","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"yoi190103r58","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1001\/archpsyc.1985.01790250028004","article-title":"Alprazolam, amitriptyline, doxepin, and placebo in the treatment of depression.","volume":"42","author":"Rickels","year":"1985","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"yoi190103r59","doi-asserted-by":"publisher","first-page":"616","DOI":"10.4088\/JCP.09m05471blu","article-title":"Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial.","volume":"71","author":"Stahl","year":"2010","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"yoi190103r60","first-page":"194","article-title":"A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients.","volume":"51","author":"Lineberry","year":"1990","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"yoi190103r61","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1097\/01.pra.0000426323.59698.64","article-title":"Efficacy and safety of desvenlafaxine 25 and 50 mg\/day in a randomized, placebo-controlled study of depressed outpatients.","volume":"19","author":"Iwata","year":"2013","journal-title":"J Psychiatr Pract"},{"key":"yoi190103r62","first-page":"883","article-title":"A dose-response and non-inferiority study evaluating the efficacy and safety of escitalopram in patients with major depressive disorder.","volume":"14","author":"Hirayasu","year":"2011","journal-title":"Jpn J Clin Psychopharmacol"},{"issue":"6","key":"yoi190103r63","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/0278-5846(90)90078-U","article-title":"A double-blind comparison of fluvoxamine, desipramine and placebo in outpatients with depression.","volume":"14","author":"Roth","year":"1990","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"1","key":"yoi190103r64","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/00004714-199802000-00004","article-title":"The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study.","volume":"18","author":"Khan","year":"1998","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"yoi190103r65","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.euroneuro.2014.01.006","article-title":"A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25-50 mg) in patients with major depressive disorder.","volume":"24","author":"Kennedy","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"yoi190103r66","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1017\/S1041610295001888","article-title":"A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression.","volume":"7","author":"Tollefson","year":"1995","journal-title":"Int Psychogeriatr"},{"issue":"3","key":"yoi190103r67","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/00004850-200205000-00001","article-title":"Escitalopram 10 mg\/day is effective and well tolerated in a placebo-controlled study in depression in primary care.","volume":"17","author":"Wade","year":"2002","journal-title":"Int Clin Psychopharmacol"},{"issue":"2","key":"yoi190103r68","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1055\/s-2006-931544","article-title":"Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study.","volume":"39","author":"Gastpar","year":"2006","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"yoi190103r69","doi-asserted-by":"publisher","first-page":"587","DOI":"10.4088\/JCP.12m08250","article-title":"The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study.","volume":"74","author":"Heun","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"5-6","key":"yoi190103r70","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1159\/000368559","article-title":"Efficacy and safety of prolonged-release trazodone in major depressive disorder: a multicenter, randomized, double-blind, flexible-dose trial.","volume":"94","author":"Zhang","year":"2014","journal-title":"Pharmacology"},{"issue":"3","key":"yoi190103r71","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1176\/appi.ajp.157.3.344","article-title":"A placebo-controlled study of fluoxetine versus imipramine in the acute treatment of atypical depression.","volume":"157","author":"McGrath","year":"2000","journal-title":"Am J Psychiatry"},{"issue":"5","key":"yoi190103r72","first-page":"661","article-title":"Efficacy of agomelatine, a MT1\/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder.","volume":"10","author":"Oli\u00e9","year":"2007","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"yoi190103r73","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.euroneuro.2005.09.002","article-title":"Placebo-controlled trial of agomelatine in the treatment of major depressive disorder.","volume":"16","author":"Kennedy","year":"2006","journal-title":"Eur Neuropsychopharmacol"},{"issue":"12","key":"yoi190103r74","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1176\/ajp.152.12.1765","article-title":"Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder.","volume":"152","author":"Lam","year":"1995","journal-title":"Am J Psychiatry"},{"issue":"9","key":"yoi190103r75","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.4088\/JCP.v64n0912","article-title":"Efficacy of controlled-release paroxetine in the treatment of late-life depression.","volume":"64","author":"Rapaport","year":"2003","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"yoi190103r76","doi-asserted-by":"publisher","first-page":"22","DOI":"10.4088\/JCP.v60n0105","article-title":"Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety: Venlafaxine XR 360 Study Group.","volume":"60","author":"Silverstone","year":"1999","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"yoi190103r77","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1097\/00004714-199604000-00003","article-title":"Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients.","volume":"16","author":"Claghorn","year":"1996","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"yoi190103r78","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1176\/ajp.139.6.803","article-title":"Trazodone in depressed outpatients.","volume":"139","author":"Rickels","year":"1982","journal-title":"Am J Psychiatry"},{"issue":"2","key":"yoi190103r79","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/BF00426739","article-title":"A placebo-controlled multicenter trial of Limbitrol versus its components (amitriptyline and chlordiazepoxide) in the symptomatic treatment of depressive illness.","volume":"61","author":"Feighner","year":"1979","journal-title":"Psychopharmacology (Berl)"},{"issue":"2","key":"yoi190103r80","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/00004850-198904000-00004","article-title":"A double-blind comparison of fluoxetine, imipramine and placebo in outpatients with major depression.","volume":"4","author":"Feighner","year":"1989","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"yoi190103r81","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0165-0327(02)00306-3","article-title":"Assessing the effects of bupropion SR on mood dimensions of depression.","volume":"78","author":"Tomarken","year":"2004","journal-title":"J Affect Disord"},{"issue":"1","key":"yoi190103r82","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s00406-004-0532-z","article-title":"Hypericum extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients.","volume":"255","author":"Bjerkenstedt","year":"2005","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"4","key":"yoi190103r84","doi-asserted-by":"publisher","first-page":"370","DOI":"10.4088\/JCP.13m08591","article-title":"A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder.","volume":"75","author":"Mischoulon","year":"2014","journal-title":"J Clin Psychiatry"},{"key":"yoi190103r85","doi-asserted-by":"publisher","first-page":"S317","DOI":"10.1097\/00002826-198406001-00286","article-title":"Fluvoxamine: antidepressant effects confirmed in a placebo-controlled international study.","volume":"7","author":"Amin","year":"1984","journal-title":"Clin Neuropharmacol"},{"issue":"10","key":"yoi190103r86","first-page":"450","article-title":"Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia.","volume":"56","author":"Guelfi","year":"1995","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"yoi190103r87","doi-asserted-by":"publisher","first-page":"e1291","DOI":"10.4088\/JCP.14m08992","article-title":"Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial.","volume":"75","author":"Croft","year":"2014","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"yoi190103r88","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1055\/s-2007-1017167","article-title":"A double-blind comparative trial of zimelidine, amitriptyline, and placebo in patients with mixed anxiety and depression.","volume":"19","author":"Amsterdam","year":"1986","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"yoi190103r89","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/00004850-198907000-00006","article-title":"A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression.","volume":"4","author":"Feighner","year":"1989","journal-title":"Int Clin Psychopharmacol"},{"issue":"4","key":"yoi190103r90","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00004850-199400940-00006","article-title":"A double-blind, placebo-controlled study comparing mianserin and amitriptyline in moderately depressed outpatients.","volume":"9","author":"Wilcox","year":"1994","journal-title":"Int Clin Psychopharmacol"},{"key":"yoi190103r91","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1600-0447.1983.tb11109.x","article-title":"Zimeldine tolerability in comparison to amitriptyline and placebo: findings from a multicentre trial.","volume":"308","author":"Claghorn","year":"1983","journal-title":"Acta Psychiatr Scand Suppl"},{"issue":"6977","key":"yoi190103r92","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1136\/bmj.310.6977.441","article-title":"Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care.","volume":"310","author":"Mynors-Wallis","year":"1995","journal-title":"BMJ"},{"issue":"8","key":"yoi190103r93","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1176\/ajp.139.8.1057","article-title":"Controlled trial of zimelidine, a 5-HT reuptake inhibitor, for treatment of depression.","volume":"139","author":"Georgotas","year":"1982","journal-title":"Am J Psychiatry"},{"issue":"1","key":"yoi190103r94","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0165-0327(88)90075-4","article-title":"Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial.","volume":"14","author":"Paykel","year":"1988","journal-title":"J Affect Disord"},{"issue":"4","key":"yoi190103r95","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1001\/2013.jamapsychiatry.32","article-title":"The sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial, randomized, controlled trial.","volume":"70","author":"Brunoni","year":"2013","journal-title":"JAMA Psychiatry"},{"issue":"1-2","key":"yoi190103r96","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/BF00431710","article-title":"Cianopramine and amitriptyline in the treatment of depressed patients\u2014a placebo-controlled study.","volume":"86","author":"Hormazabal","year":"1985","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"yoi190103r97","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/00004714-200002000-00006","article-title":"Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder.","volume":"20","author":"Versiani","year":"2000","journal-title":"J Clin Psychopharmacol"},{"issue":"3, pt 2","key":"yoi190103r98","first-page":"26","article-title":"A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder.","volume":"46","author":"Cohn","year":"1985","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"yoi190103r99","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1176\/ajp.141.4.525","article-title":"A double-blind study of bupropion and placebo in depression.","volume":"141","author":"Feighner","year":"1984","journal-title":"Am J Psychiatry"},{"key":"yoi190103r100","first-page":"53","article-title":"Estudio doble ciego con antidepressivo, psicoterapia breve y placebo en pacientes con depression leve a moderada.","volume":"27","author":"Rodriguez","year":"2004","journal-title":"Salud Mental"},{"issue":"7","key":"yoi190103r101","first-page":"250","article-title":"Trazodone, a triazolopyridine derivative, in primary depressive disorder.","volume":"41","author":"Feighner","year":"1980","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"yoi190103r102","first-page":"907","article-title":"Neuropsychological assessment and EEG sleep in affective disorders.","volume":"16","author":"Shipley","year":"1981","journal-title":"Biol Psychiatry"},{"issue":"2","key":"yoi190103r103","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/00004714-198103000-00006","article-title":"A controlled study of trazodone, imipramine, and placebo in outpatients with endogenous depression.","volume":"1","author":"Mann","year":"1981","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"yoi190103r104","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.psychres.2011.12.051","article-title":"Heterogeneity and symptom structure of schizophrenia.","volume":"198","author":"Picardi","year":"2012","journal-title":"Psychiatry Res"},{"issue":"1","key":"yoi190103r105","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.schres.2013.05.028","article-title":"Definition and description of schizophrenia in the DSM-5.","volume":"150","author":"Tandon","year":"2013","journal-title":"Schizophr Res"},{"key":"yoi190103r106","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jad.2014.09.032","article-title":"An adaptationist perspective on the etiology of depression.","volume":"172","author":"Durisko","year":"2015","journal-title":"J Affect Disord"},{"key":"yoi190103r107","first-page":"4","article-title":"The varied clinical presentations of major depressive disorder.","volume":"68","author":"Rush","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"yoi190103r108","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1017\/S0033291718001708","article-title":"Personalized prediction of antidepressant v. placebo response: evidence from the EMBARC study.","volume":"49","author":"Webb","year":"2019","journal-title":"Psychol Med"},{"issue":"11","key":"yoi190103r109","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1001\/jamapsychiatry.2015.1516","article-title":"Baseline depression severity as moderator of depression outcomes between cognitive behavioral therapy vs pharmacotherapy: an individual patient data meta-analysis.","volume":"72","author":"Weitz","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"11","key":"yoi190103r110","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1176\/appi.ajp.161.11.2050","article-title":"Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial.","volume":"161","author":"Roose","year":"2004","journal-title":"Am J Psychiatry"},{"key":"yoi190103r111","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3389\/fpsyg.2011.00159","article-title":"Blue again: perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression.","volume":"2","author":"Andrews","year":"2011","journal-title":"Front Psychol"},{"issue":"2","key":"yoi190103r112","first-page":"58","article-title":"Are SNRIs more effective than SSRIs? a review of the current state of the controversy.","volume":"41","author":"Thase","year":"2008","journal-title":"Psychopharmacol Bull"},{"issue":"3","key":"yoi190103r113","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3109\/15622970209150611","article-title":"Old and new antidepressants: where are we?","volume":"3","author":"Ayuso-Guti\u00e9rrez","year":"2002","journal-title":"World J Biol Psychiatry"},{"issue":"6","key":"yoi190103r114","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.18m12483","article-title":"Predicting remission in late-life major depression: a clinical algorithm based upon past treatment history","volume":"80","author":"Buchalter","year":"2019","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"yoi190103r115","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"6","key":"yoi190103r116","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1017\/S0033291711002170","article-title":"Is prior course of illness relevant to acute or longer-term outcomes in depressed out-patients? a STAR*D report.","volume":"42","author":"Rush","year":"2012","journal-title":"Psychol Med"},{"key":"yoi190103r1","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","edition":"5th ed"},{"key":"yoi190103r19","author":"Stone"},{"key":"yoi190103r23","doi-asserted-by":"crossref","DOI":"10.1002\/9781118511800","volume-title":"Clinical Psychometrics","author":"Bech","year":"2012"},{"key":"yoi190103r24","volume-title":"Structured Interview Guide for the Hamilton Depression Rating Scale, Seasonal Affective Disorders Version (SIGH-SAD)","author":"Williams","year":"1988"},{"key":"yoi190103r25","author":"Roberts","year":"2001"},{"key":"yoi190103r2","unstructured":"National Institute for Health and Care Excellence. Depression in adults: recognition and management: clinical guideline. https:\/\/www.nice.org.uk\/guidance\/cg90\/resources\/depression-in-adults-recognition-and-management-pdf-975742638037. Published October 28, 2009. Accessed January 9, 2020."},{"key":"yoi190103r31","unstructured":"Open Science Foundation. Cipriani Opendata Var (Version 1). https:\/\/mfr.ca-1.osf.io\/render?url=https:\/\/osf.io\/nek7a\/?action=download%26mode=render. Accessed November 24, 2019."},{"key":"yoi190103r32","unstructured":"Open Science Foundation. #Evidence of individual differences in response to ADs. https:\/\/mfr.ca-1.osf.io\/render?url=https:\/\/osf.io\/n9exr\/?action=download%26mode=render. Accessed November 24, 2019."},{"key":"yoi190103r34","unstructured":"IQWiG. Studieninformationen zu Reboxetin. https:\/\/www.iqwig.de\/de\/projekte-ergebnisse\/studieninformationen-zu-reboxetin.3304.html. Accessed January 9, 2020."},{"key":"yoi190103r36","unstructured":"ClinicalTrials.gov. A placebo- and paroxetine-controlled study of the efficacy, safety and tolerability of agomelatine (25 or 50 mg) in the treatment of major depressive disorder (MDD). NCT0046342. https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT00463242. Accessed January 9, 2020."},{"key":"yoi190103r37","unstructured":"European Medicines Agency. CHMP assessment report for Thymanax. https:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/000916\/WC500038315.pdf. Accessed January 9, 2020."},{"key":"yoi190103r40","unstructured":"Center for Drug Evaluation and Research. Application number: 022567Orig1s000. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2011\/022567Orig1s000MedR.pdf. Accessed January 9, 2020."},{"key":"yoi190103r41","unstructured":"Mirtazapine. https:\/\/digitalcollections.ohsu.edu\/concern\/etds\/p8418n49j. Accessed January 9, 2020."},{"key":"yoi190103r49","unstructured":"European Medicines Agency. CHMP assessment report for Valdoxan. https:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/000915\/WC500046226.pdf. Accessed January 9, 2020."},{"key":"yoi190103r50","unstructured":"Clinical evaluation of bupropion sustained release (SR) in patients with depression\u2014placebo-controlled, double-blind, comparative study in patients with depression who did not respond sufficiently to selective serotonin re-uptake inhibitors. https:\/\/s3.amazonaws.com\/ctr-gsk-7381\/AK1102365\/bee55eb8-76ee-4a6b-ade4-8a5065394c20\/90d88af2-550c-426c-88ed-38b86af0ce6d\/20464-v1.pdf. Accessed January 9, 2020."},{"key":"yoi190103r57","unstructured":"GSK. A study to assess the effectiveness and tolerance of paroxetine by double-blind comparison with placebo and mianserin. https:\/\/s3.amazonaws.com\/ctr-gsk-7381\/29060_012_3\/393e5532-4b36-4619-a5b7-404942078424\/fcd71439-5af1-479f-b98f-dea091c1d6c3\/2866-v1.pdf. Accessed January 9, 2020."},{"key":"yoi190103r83","unstructured":"GSK. Study description: phase II multicenter evaluation of the efficacy and safety of bupropion vs. placebo in depressed inpatients. https:\/\/s3.amazonaws.com\/ctr-gsk-7381\/14\/463b736d-71c7-40e6-83ef-5f19c1583c6d\/32ef7a6d-bf9f-440d-9212-5f5d8115a158\/769-v1.pdf. Accessed January 9, 2020."}],"updated-by":[{"DOI":"10.1001\/jamapsychiatry.2020.2026","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T00:00:00Z","timestamp":1591747200000},"record-id":"23556"}],"container-title":["JAMA Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/articlepdf\/2761561\/jamapsychiatry_maslej_2020_oi_190103_1770228040.83055.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T18:30:28Z","timestamp":1770229828000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapsychiatry\/fullarticle\/2761561"}},"subtitle":["A Meta-analysis of Placebo-Controlled Randomized Clinical Trials"],"short-title":[],"issued":{"date-parts":[[2020,6,1]]},"references-count":116,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.4815","relation":{},"ISSN":["2168-622X"],"issn-type":[{"value":"2168-622X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6,1]]}}}